|
US7988993B2
|
|
Oral controlled release dosage form
|
|
US6905708B2
|
|
Controlled release oral dosage form
|
|
US6893660B2
|
|
Stable pharmaceutical compositions without a stabilizer
|
|
US7642286B2
|
|
Stable pharmaceutical compositions containing pravastatin
|
|
CA2796884A1
|
|
Improved controlled release oral dosage form
|
|
AU2024802A
|
|
Once a day antihistamine and decongestant formulation
|
|
US6589553B2
|
|
Controlled release oral dosage form
|
|
US6733778B1
|
|
Omeprazole formulation
|
|
NZ510231A
|
|
Omeprazole formulation comprising an alkaline core and an enteric coating
|
|
WO9961005A1
|
|
Controlled release oral dosage form
|
|
US6210716B1
|
|
Controlled release bupropion formulation
|
|
CA2586240A1
|
|
Improved hmg coa reductase inhibitor extended release formulation
|
|
AU1627599A
|
|
Improved HMG CoA reductase inhibitor extended release formulation
|
|
US6270805B1
|
|
Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
|
|
US6174548B1
|
|
Omeprazole formulation
|
|
US6524620B2
|
|
Diltiazem controlled release formulation and method of manufacture
|
|
US6197347B1
|
|
Oral dosage for the controlled release of analgesic
|
|
US6099859A
|
|
Controlled release oral tablet having a unitary core
|
|
US6485748B1
|
|
Once daily pharmaceutical tablet having a unitary core
|
|
US6096340A
|
|
Omeprazole formulation
|
